GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40938)

  • GC81301 structure
    GC81301BSJ-04-146
    CAS: 2414478-45-6
    Purity: >98.00%

    BSJ-04-146 is a highly efficient and selective PROTAC targeting focal adhesion kinase ( FAK ) inhibitor( IC 50 = 26 nM).

  • GC81302 structure
    GC81302Asciminib-NH2
    CAS: 3106065-83-9
    Purity: >97.00%

    Asciminib-NH2 is a BCR-ABL ligand and can be used for the synthesis of PROTACs, such as P19As [1] .

  • GC81303 structure
    GC81303PROTAC AR Degrader-12
    Purity: >98.50%

    PROTAC AR Degrader-12 is a highly efficient PROTAC targeting AR coactivator binding site (AR-CBS).

  • GC81304 structure
    GC81304GW296115
    CAS: 118458-58-5
    Purity: >98.50%

    GW296115 is a multi-target inhibitor with the following IC 50 values against its targets: 8.4 nM for BRSK2, 21 nM for BRSK1, 1.8 μM for PDGFRβ, 5.5 nM for STK17B/DRAK2, 28 nM for DRAK1, 20 nM for PHKG1, and 89 nM for DCAMKL3.

  • GC81305 structure
    GC81305Tyrosine kinase-IN-11
    CAS: 3031972-21-8
    Purity: >98.50%

    Tyrosine kinase-IN-11 (Compound 4b) is a tyrosine kinase inhibitor.

  • GC81306 structure
    GC81306PRT-060318 dihydrochloride
    CAS: 3032567-93-1
    Purity: >98.50%

    PRT-060318 (PRT318) dihydrochloride is a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC 50 of 3 nM.

  • GC81307 structure
    GC81307DYRK2-IN-2
    CAS: 2416195-65-6
    Purity: >98.00%

    DYRK2-IN-2 (Compound C17) is a selective inhibitor of DYRK2, with its IC 50 value being 40.3 nM.

  • GC81308 structure
    GC81308DYRK2-IN-2 hydrochloride
    Purity: >98.00%

    DYRK2-IN-2 hydrochloride is a selective DYRK2 inhibitor with an IC 50 of 40.3 nM.

  • GC81309 structure
    GC81309AO-365/43472821
    CAS: 1081122-55-5
    Purity: >99.50%

    AO-365/43472821 is a selective, brain-penetrant Dual-specificity tyrosine phosphorylation-regulated kinase 1A ( DYRK1A ) inhibitor ( IC 50 = 0.29 μM) and shows a significant inhibitory effect on ( CDC-like kinase 1) CLK1 ( IC 50 = 0.08 μM).

  • GC81310 structure
    GC81310c-Kit-IN-16
    Purity: >99.00%

    C-Kit-IN-16 is a c-kit inhibitor with an IC 50 of 25 nM.

  • GC81311 structure
    GC81311HGF-IN-1
    CAS: 874744-59-9
    Purity: >98.00%

    HGF-IN-1 ((the compound on the left in the second line of page 77) is a HGF inhibitor.

  • GC81312 structure
    GC81312PARP1/c-Met-IN-3
    CAS: 3123529-62-1
    Purity: >98.00%

    PARP1/c-Met-IN-3 (Compound L19) is a selective c-Met and PARP1 inhibitor, with an IC 50 of 5.4 nM against c-Met and an IC 50 of 3.7 nM against PARP1.

  • GC81313 structure
    GC81313STARD3-IN-1
    CAS: 1424357-72-1
    Purity: >99.00%

    STARD3-IN-1 (Compound VS1) is a STARD3 inhibitor with an IC₅₀ of 35 μM.

  • GC81314 structure
    GC81314OM-RCA-01
    Purity: >99.00%

    OM-RCA-01 is an anti- FGFR1 monoclonal antibody with a K d of 1.59 nM for human FGFR1.

  • GC81315 structure
    GC81315Lck-IN-5
    CAS: 1356734-45-6
    Purity: >98.00%

    Lck-IN-5 (example C10) is a potent and selective lymphocyte-specific protein tyrosine kinase ( LCK ) inhibitor.

  • GC81316 structure
    GC81316RC148
    Purity: >99.50%

    RC148 is a humanized IgG1 bispecific antibody targeting VEGF and PD-1.

  • GC81317 structure
    GC81317PP185
    CAS: 851176-40-4
    Purity: >98.00%

    PP185 is a insulin receptor kinase substrate.

  • GC81318 structure
    GC81318GIPR antagonist 2
    CAS: 3105300-99-7
    Purity: >99.00%

    GIPR antagonist 2 is a glucose-dependent insulinotropic polypeptide receptor ( GIPR ) antagonist with an IC 50 of 7.2 nM in CHO-K1 cells.

  • GC81319 structure
    GC813192,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose
    CAS: 150302-84-4
    Purity: >98.00%

    2,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose is an FGFR3 and BRAF binder, and is an isovaleryl sucrose ester that can be found in Atractylodes japonica.

  • GC81320 structure
    GC81320Papaveroline
    CAS: 574-77-6
    Purity: >98.00%

    Papaveroline is a Fyn tyrosine kinase inhibitor, Na +,K + -ATPase inhibitor with an IC 50 of 0.20 mM, Mg 2+ -ATPase inhibitor, K + -activated pNPPase inhibitor with an IC 50 of 1.51 mM, and apoptosis inducer [1] [2] [3] . Papaveroline binds to the active site of Fyn tyrosine kinase and forms stable interactions with pocket amino acid residues [1] . Papaveroline induces cell apoptosis, produces pycnotic and fragmented cell nuclei, and does not reduce intracellular ATP levels [3] . Papaveroline is a dopamine-derived neurotoxin candidate associated with the pathogenesis of Parkinson's disease [3] . Papaveroline can be used in the research of Alzheimer's disease and Parkinson's disease [3] .

  • GC81321 structure
    GC81321Pegpleranib sodium
    Purity: >98.00%

    Pegpleranib (Fovista) sodium is a pegylated DNA aptamer that selectively binds to PDGF-BB and PDGF-AB homodimers and heterodimers, interrupting the interaction with their associated tyrosine kinase receptors.

  • GC81322 structure
    GC81322PF-07245303
    CAS: 2655556-75-3
    Purity: >98.00%

    PF-07245303 is a ITK / TRK inhibitor.

  • GC81323 structure
    GC81323PDGFRA/CAIX/XII-IN-1
    Purity: >98.00%

    PDGFRA/CAIX/XII-IN-1 is an inhibitor of PDGFRA, CA IX and CA XII, with an IC 50 of 20 nM against PDGFRA, a K i of 93.3 nM against CA IX, and a K i of 80.0 nM against CA XII.

  • GC81324 structure
    GC81324FGF7p
    CAS: 2758194-43-1
    Purity: >99.00%

    FGF7p is a small molecule peptide and a potential bladder protector.